DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,313,933 | -30.8% | 354,529 | -1.1% | 0.03% | -25.7% |
Q2 2023 | $10,575,853 | +58.7% | 358,382 | +23.9% | 0.04% | +52.2% |
Q1 2023 | $6,664,136 | -17.3% | 289,242 | -0.2% | 0.02% | -20.7% |
Q4 2022 | $8,062,675 | -47.2% | 289,920 | -41.7% | 0.03% | -3.3% |
Q3 2022 | $15,269,813 | +4.7% | 497,544 | +0.4% | 0.03% | +11.1% |
Q2 2022 | $14,579,546 | +13.0% | 495,382 | +23.5% | 0.03% | +50.0% |
Q1 2022 | $12,904,273 | +31.5% | 401,136 | +82.3% | 0.02% | -28.0% |
Q4 2021 | $9,815,000 | -3.5% | 220,066 | +9.2% | 0.02% | -13.8% |
Q3 2021 | $10,170,000 | -64.5% | 201,580 | -44.8% | 0.03% | -29.3% |
Q2 2021 | $28,662,000 | +183.6% | 365,400 | +106.5% | 0.04% | +32.3% |
Q1 2021 | $10,105,000 | -23.7% | 176,978 | +11.9% | 0.03% | -26.2% |
Q4 2020 | $13,250,000 | +65.8% | 158,190 | -29.1% | 0.04% | +44.8% |
Q3 2020 | $7,993,000 | -26.6% | 223,071 | -50.5% | 0.03% | +38.1% |
Q2 2020 | $10,890,000 | +65.5% | 450,380 | +19.8% | 0.02% | +31.2% |
Q1 2020 | $6,582,000 | – | 375,924 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 19,462,500 | $298,165,000 | 48.02% |
Bratton Capital Management, L.P. | 953,035 | $14,600,000 | 28.53% |
Flagship Pioneering Inc. | 8,005,747 | $122,648,000 | 6.71% |
Casdin Capital, LLC | 650,000 | $9,958,000,000 | 1.03% |
Temasek Holdings (Private) Ltd | 4,410,457 | $67,568,000 | 0.50% |
MARK ASSET MANAGEMENT LP | 68,864 | $1,055,000 | 0.26% |
IRONWOOD INVESTMENT MANAGEMENT LLC | 22,507 | $345,000 | 0.26% |
Artal Group S.A. | 400,000 | $6,128,000 | 0.25% |
PIER 88 INVESTMENT PARTNERS LLC | 40,610 | $622,000 | 0.24% |
HAMILTON LANE ADVISORS LLC | 30,948 | $474,000 | 0.20% |